No Data
Vaccinex Announces Signing Of Proprietary Project Agreements With Amgen, Merck, Chugai, Absci, Gigagen, Merus, Soleil, ThirdArc And Incyte To Employ Vaccinex's ActivMAb Technology
Merus to Present at Upcoming Investor Conferences
CCORF Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $67
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Fresenius Medical Care (FMS) and Treace Medical Concepts (TMCI)
Express News | U.s-Listed Shares of Merus NV Down 4.5% After FDA Extends Review of Co's Gene-Targeting Cancer Therapy
Merus Receives FDA Extension of PDUFA for Zenocutuzumab
No Data
No Data